Aztreonam Lysine for Inhalation Solution in Cystic Fibrosis
Explore this paper's citation graph
Summary
Aztreonam lysine for inhalation solution was associated with a significant delay in the need for inhaled or intravenous antipseudomonal antibacterials, as determined by the presence of one of four predefined symptoms shown to be predictive of pulmonary exacerbations.
- Type
- article
- Published
- 2011-04-01
- Cited by
- 19
- References
- 28
- OpenAlex
- https://openalex.org/W52196773
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:30842151
Keywords
Cystic fibrosis, Medicine, Inhalation, Aztreonam, Pharmacotherapy
References
- Aerosol treatment of cystic fibrosis.
- Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride).
- Antibiotic treatment. Aerosol therapy.
- Administration of aerosolized antibiotics in cystic fibrosis patients.
- Aztreonam Lysine for Inhalation Solution
- Nebulized Antibiotics in Cystic Fibrosis
- Defining a pulmonary exacerbation in cystic fibrosis.
- Clonidine in benzodiazepine withdrawal.
- An 18-Month Study of the Safety and Efficacy of Repeated Courses of Inhaled Aztreonam Lysine in Cystic Fibrosis
- Tissue injury caused by deposition of immune complexes is L-arginine dependent.
- A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection
- Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis
- Inhaled L-arginine improves exhaled nitric oxide and pulmonary function in patients with cystic fibrosis.
- Inhaled antibiotics in cystic fibrosis.
- A double-blind, multinational, randomized, placebo-controlled trial evaluating aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF), mild lung disease and P. aeruginosa (PA)
- Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis.
- Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis.
- Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.
- Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection.
- Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.
Cited by
- Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead
- Current dilemmas in antimicrobial therapy in cystic fibrosis
- Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review
- Aztreonam lysine for inhalation: new formulation of an old antibiotic.
- Clinical Pharmacokinetics of Inhaled Antimicrobials
- Susceptibility of Pseudomonas aeruginosa Urinary Tract Isolates and Influence of Urinary Tract Conditions on Antibiotic Tolerance
- Spanish consensus on the prevention and treatment of Pseudomonas aeruginosa bronchial infections in cystic fibrosis patients
- Aerosolized antibiotics in cystic fibrosis: an update
- Inhaled Aztreonam Lysine for Cystic Fibrosis Pulmonary Disease–Related Outcomes
- Aztreonam Lysine Inhalation Solution in Cystic Fibrosis
- Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
- Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
- Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis.
- Cystic Fibrosis and Bronchiectasis
- panish Consensus on the Prevention and Treatment of Pseudomonas eruginosa Bronchial Infections in Cystic Fibrosis Patients
- Penicillins, Cephalosporins, Other Beta-Lactam Antibiotics and Tetracyclines
- Spanish Consensus on the Prevention and Treatment of Pseudomonas aeruginosa Bronchial Infections in Cystic Fibrosis Patients (cid:2)
Related papers
- Stability of aztreonam in a portable pump reservoir used for home intravenous antibiotic treatment (HIVAT)
- Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain.
- In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases.
- The in-vitro activity of SQ 82,291, a new monobactam, in comparison with aztreonam.
- Enzymatic inactivation of aztreonam by faecal enzyme preparations from healthy volunteers
- Absence of rapidly developing resistance during treatment of cystic fibrosis patients with aztreonam.
- Comparative metabolomics reveal key pathways associated with the synergistic activities of aztreonam and clavulanate combination against multidrug-resistant Escherichia coli
- Comparative efficacies of aztreonam and chloramphenicol in children with typhoid fever